{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Regorafenib&page=2", "query": { "intervention": "Regorafenib", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Regorafenib&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-25T16:40:11.565Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05064059", "title": "A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "favezelimab/pembrolizumab", "type": "BIOLOGICAL" }, { "name": "regorafenib", "type": "DRUG" }, { "name": "TAS-102", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 441, "start_date": "2021-11-10", "completion_date": "2025-02-21", "has_results": true, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-09-25T16:40:11.565Z", "location_count": 15, "location_summary": "Washington D.C., District of Columbia • Marietta, Georgia • Louisville, Kentucky + 11 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05064059" }, { "nct_id": "NCT05731947", "title": "Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Solid Tumors" ], "interventions": [ { "name": "Revumenib", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Syndax Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2023-04-04", "completion_date": "2025-06-30", "has_results": true, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-25T16:40:11.565Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Boston, Massachusetts • Manhattan, New York + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Manhattan", "state": "New York" }, { "city": "Canton", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05731947" }, { "nct_id": "NCT03042689", "title": "Study of Regorafenib in Patients With Advanced Myeloid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2017-04-17", "completion_date": "2023-02-27", "has_results": false, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-09-25T16:40:11.565Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03042689" }, { "nct_id": "NCT02551718", "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Recurrent Acute Leukemia of Ambiguous Lineage", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Acute Leukemia of Ambiguous Lineage" ], "interventions": [ { "name": "Chemosensitivity Assay", "type": "OTHER" }, { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Gene Expression Analysis", "type": "GENETIC" }, { "name": "Genetic Variation Analysis", "type": "GENETIC" }, { "name": "In Vitro Sensitivity-Directed Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "OTHER", "GENETIC", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 34, "start_date": "2015-09-11", "completion_date": "2021-05-13", "has_results": true, "last_update_posted_date": "2022-06-30", "last_synced_at": "2026-09-25T16:40:11.565Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02551718" }, { "nct_id": "NCT02053376", "title": "A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Biliary Tract Carcinoma" ], "interventions": [ { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nathan Bahary, MD", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2014-01", "completion_date": "2018-05-14", "has_results": true, "last_update_posted_date": "2019-01-30", "last_synced_at": "2026-09-25T16:40:11.565Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02053376" }, { "nct_id": "NCT06029010", "title": "An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Regorafenib (Stivarga, BAY73-4506)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 2326, "start_date": "2023-08-31", "completion_date": "2025-01-27", "has_results": false, "last_update_posted_date": "2025-02-26", "last_synced_at": "2026-09-25T16:40:11.565Z", "location_count": 1, "location_summary": "Multiple Locations, New Jersey", "locations": [ { "city": "Multiple Locations", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06029010" }, { "nct_id": "NCT01117623", "title": "Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm" ], "interventions": [ { "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg", "type": "DRUG" }, { "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg", "type": "DRUG" }, { "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg", "type": "DRUG" }, { "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg", "type": "DRUG" }, { "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg", "type": "DRUG" }, { "name": "HCC Child-Pugh A expansion cohort: Regorafenib 100 mg", "type": "DRUG" }, { "name": "HCC Child-Pugh B expansion cohort: Regorafenib 100 mg", "type": "DRUG" }, { "name": "NSCLC expansion cohort: Regorafenib 100 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2007-02", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2015-11-18", "last_synced_at": "2026-09-25T16:40:11.565Z", "location_count": 5, "location_summary": "Los Angeles, California • Aurora, Colorado • Houston, Texas + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01117623" }, { "nct_id": "NCT05198934", "title": "Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer (CRC)" ], "interventions": [ { "name": "Sotorasib", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" }, { "name": "Trifluridine and Tipiracil", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 160, "start_date": "2022-04-19", "completion_date": "2026-04-14", "has_results": true, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-25T16:40:11.565Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Duarte, California • Orange, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05198934" }, { "nct_id": "NCT02096354", "title": "A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "RRx-001", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EpicentRx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2014-05", "completion_date": "2020-10-08", "has_results": true, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-09-25T16:40:11.565Z", "location_count": 5, "location_summary": "La Jolla, California • Stanford, California • Honolulu, Hawaii + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02096354" }, { "nct_id": "NCT01271712", "title": "Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastrointestinal Stromal Tumors" ], "interventions": [ { "name": "Regorafenib (Stivarga, BAY73-4506)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Best supportive care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 199, "start_date": "2011-01-04", "completion_date": "2019-04-15", "has_results": true, "last_update_posted_date": "2021-01-29", "last_synced_at": "2026-09-25T16:40:11.565Z", "location_count": 9, "location_summary": "Scottsdale, Arizona • Evanston, Illinois • Skokie, Illinois + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01271712" } ] }